Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. (OTCBB: ENTB) a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

David Koos, Chairman and CEO of Bio-Matrix Scientific Group and its majority owned subsidiary, Entest BioMedical, Inc. says, “Our goal with this research is to test a viable and groundbreaking cancer treatment, first in the veterinary oncology market and then, if successful, to move on to human clinical trials.”

The Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process will utilize an implantable chamber device as the vaccine delivery system. This process has already been demonstrated effective on treating tumors in both rodent and canine models. The grant application has already been assigned to a Scientific Review Group for scientific merit evaluation.

Principal Investigator Dr. Steven F. Josephs says, “If successful, this approach reduces the need for chemotherapy or radiation treatments since the enhanced immune system is engaged in eliminating cancerous tissue on its own. In doing this, we are allowing the subject to recover without the damage that generally occurs with more traditional cancer treatments.” Josephs continues, “This work, if successful, should result in a groundbreaking discovery for cancer therapy.”

Once efficacy has been achieved in this study, the Company plans to develop a commercially viable treatment for canines, which could impact approximately 36 million dogs in United States that suffer from cancer, according to the Morris Animal Foundation and the American Veterinary Medical Association.